H.C. Wainwright analyst Douglas Tsao maintains $Sage Therapeutics (SAGE.US)$ with a hold rating, and maintains the target price at $25.
According to TipRanks data, the analyst has a success rate of 45.8% and a total average return of 12.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Sage Therapeutics observed its Phase 2 LIGHTWAVE study evaluating dalzanemdor in Alzheimer's disease fail to meet the primary endpoint. Consequently, the company has decided to halt the drug's development for this indication. While Sage anticipates topline Phase 2 results from the DIMENSION trial for Huntington's later in the year, and some clinical validation stems from initial positive SURVEYOR data, it is suggested that substantial clinical validation is required to mitigate the risks associated with the program.
Sage Therapeutics' Phase 2 LIGHTWAVE study of dalzanemdor for mild AD/MCI did not meet the primary endpoint, as it failed to show a statistically significant improvement from baseline on the WAIS-IV score. Despite this outcome not affecting prior estimates, the company has decided to halt further development of dalzanemdor in AD. However, Sage continues to await the forthcoming DIMENSION study results for Huntington's disease expected in Q4 2024. Analysts express caution regarding the potential for positive outcomes in the Huntington's study, given the historical challenges encountered with dalzanemdor.
Sage Therapeutics disclosed the unsuccessful outcome of the phase 2 LIGHTWAVE trial of dalzanemdor in Alzheimer's disease, which is likely to shift the entire investment community's attention principally towards Zurzuvae in future evaluations.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
